You are here

Funding Opportunities

Updated November 30, 2018

Tri-council:

CIHR has launched an online linkage tool designed to assist researchers and other stakeholders in identifying and connecting with potential partners to develop their projects.
CIHR Project Grant Spring 2019
  • Registration Deadline: Feb 6, 2019
  • Application Deadline    Mar 6, 2019
  • Spring 2019 Priority Announcement (Specific Research Areas) - to be announced
SSHRC Connections Grant
  • $7,000 to $25,000 for events, and up to $50,000 for other outreach activities; higher amounts for outreach activities may be considered if well justified
  • Application Deadlines (4 cycles/year): Feb 1, 2019
  • Connection Grants support workshops, colloquiums, conferences, forums, summer institutes, or other events or outreach activities that facilitate:
  • disciplinary and/or interdisciplinary exchanges in the humanities and social sciences;
  • scholarly exchanges between those working in the social sciences and humanities and those working in other research fields;
  • intersectoral exchanges between academic researchers in the humanities and social sciences and researchers and practitioners from the public, private and/or not-for-profit sectors; and/or
  • international research collaboration and scholarly exchanges with researchers, students and non-academic partners from other countries.
NSERC- Engage Grants
  • $25,000 for 6 months. At minimum, an in-kind contribution from the company reflecting its active involvement in the project is required
  • Support a new research collaboration with an industrial partner through a short-term research and development (R&D) project that applies their expertise to address a company challenge.
  • Rolling deadline
Government of Canada: Going Global Innovation (GGI) 
  • The GGI program is specifically designed to promote and enhance Canada’s international innovation efforts. The program supports researchers who aim to commercialize technology by pursuing collaborative international research and development (R&D) opportunities through partnerships with key players in foreign markets. Eligible beneficiaries are Canadian innovators from small or medium size enterprises, universities and nongovernment research centres.
  • GGI provides assistance by contributing up to 75% of eligible expenses, up to a maximum of $75,000 for any approved project. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.
  • Application Deadline: Continuous.

Other Canadian Funding competitions:

UBC-V: CFI Innovation Fund – Expression of Interest
  • Faculty on the Vancouver campus are invited to submit an internal EOI for the Canada Foundation for Innovation’s (CFI) Innovation Fund by Jan. 11, 2019.
Broad Medical Research Program at CCFA (BMRP-CCFA): Inflammatory Bowel Disease Grants
  • For innovative proposals (clinical or basic) that will lead to improvements in the prevention, diagnosis or therapy of Crohn’s disease or ulcerative colitis. Preference is given to proposals for work conducted with human samples or patients. Research using non-human material should lead to translational benefits to patients with IBD.
  • There is no fixed upper or lower limit of funding, but applicants should keep in mind that BMRP-CCFA has limited funds. Funding can be requested for up to two years, but grants generally are funded only one year at a time.
  • LoI is accepted all year round.

    International Funding competitions:

    USA NIH:

    NIH Heal Initiative
    • As part of the HEAL (Helping to End Addiction Long-term) Initiative, NIH will support research on how chronic pain develops and on new treatments to alleviate chronic pain.  HEAL will develop a data sharing collaborative, new biomarkers for pain, and a clinical trials network for testing new pain therapies
    • Notices of Intent to Publish FOAs for a Clinical Trials Network on Pain Research
    NOT-TR-19-007: Tissue Chips to Model Nociception, Addiction, and Overdose
    • The FOA is expected to be published in December 2018, with an expected application due date in February 2019. Please see NOT-TR-19-007 for more information.
    RFA-DA-18-012: Development of a Device to Objectively Measure Pain (R43/R44)
    • The purpose of this Small Business Innovation Research (SBIR) Funding Opportunity Announcement (FOA) is to develop a technology/device that objectively indicates the presence and level of pain.
    • Cycle II: January 5, 2019
    • Cycle III: April 5, 2019
    Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R41/R42)
    • Seeks small business organizations to develop opioid and adjuvant drug combinations within a single dosage form for treatment of a pain condition.
    • Cycle II: January 5, 2019
    • Cycle III: April 5, 2019
    PAR-18-742: Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)
    • Encourages research that investigates the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance, or treatment of chronic pain. Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications or to develop biomarkers that predict chronic pain progression or treatment response.
    • LOI due Jan 11, 2019; Application due date: Feb 11, 2019
    PAR-14-182: Exploratory Clinical Trials of Mind and Body Interventions for NCCAM High Priority Research Topics (R34)
    • Supports early phase clinical trials of mind and body approaches for conditions that have been identified by NCCAM as high priority research topics.
    • Cycle I due date
    PAS-18-624: Mechanistic Investigations of Psychosocial Stress Effects on Opioid Use Patterns (R01: Clinical Trial Optional)
    • Seeks to address two specific mechanistic pathways via which psychosocial stress may modulate opioid use trajectories.
      • The first pathway is through its effects on cognitive and affective systems that are also altered in OUDs.
      • Second related pathway is substantial co-morbidity between OUD and stress-related affective disorders, including depression, anxiety and PTSD.
    • Cycle I due date: January 25, 2019
    PA-18-376, PA-14-474, PA-14-384: Self-Management for Health in Chronic Conditions (R01, R15, R21)
    • Cycle I due date: January 25, 2019
    PPA-15-141, PA-15-142, PA-15-143: International Research Collaborations on Drug Abuse and Addiction Research (R03, R01, R21)
    • Cycle I due date: January 25, 2019
    PAR-14-225: Neurobiology of Migraine (R01)
    • Supports innovative research that will elucidate the mechanisms underlying migraine; expand our current knowledge of the role of genetic, physiological, biopsychosocial, and environmental influences in migraine susceptibility and progression; and explore new therapeutic targets and therapies for acute migraine management and longer-term prevention.
    • Cycle I due date: January 25, 2019
    PA-16-311, PA-16-313, PA-16-312: Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R01, R03, R21)
    • Promotes preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations
    • Develops effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments
    • Budgets are not limited but need to reflect the actual needs of the proposed project
    • Maximum of 5 years
    • Cycle I due date: January 25, 2019
    PA-18-944: Biobehavioral Basis of Chronic Pain (R01)
    • The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience.
    • Cycle I due date: February 5, 2019
    PA-14-244: Research on Chronic Overlapping Pain Conditions (R01)
    • The purpose of this Funding Opportunity Announcement (FOA) is to encourage epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain.
    • Cycle I due date: February 5, 2019
    RFA-NS-18-041: Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
    • Purpose is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints. Although research supported by this FOA can include animal studies, it must also include preliminary human validation using carefully standardized human samples or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.
    • Letter of Intent due Feb 7; Application due Mar 7 2019
    PA-18-945: Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01)
    • The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.
    • The first standard application due date for this FOA is February 16, 2019.
    PAS-18-625: Mechanistic Investigations of Psychosocial Stress Effects on Opioid Use Patterns (R21: Clinical Trial Optional)
    • This funding opportunity announcement (FOA) invites innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD).
    • LOI due Jan 16, 2019; Application due Feb 16, 2019
    PA-18-943: Biobehavioral Basis of Chronic Pain (R21)
    • The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain.  The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.
    • The first standard application due date for this FOA is February 16, 2019.

    Other USA Opportunities:

    2019 Rita Allen Foundation Award in Pain
    • The Rita Allen Foundation (RAF) and American Pain Society (APS) announce the 2019 Award in Pain. The RAF and APS may award two grants in the amount of $50,000 annually, for a period of up to three years to those research proposals demonstrating the greatest merit and potential for success.
    • Application due date: Dec 17, 2018
    American Orthopaedic Society for Sports Medicine: Osteoarthritis Basic Science Research Grant
    • Supports either a clinical research study or a lab/basic science project in the areas of early osteoarthritis and/or the prevention of OA progression
    • $50,000 for 1 year
    • Due Jan 1, 2019
    New Funding Opportunity for Pain Research Through OnPAR:
    • OnPAR provides innovative and exceptional research applications with a second opportunity for funding
    • OnPAR seeks to provide a funding alternative to the research community’s restraints imposed by limitations in government funding. OnPAR members include private foundations, pharmaceuticals and other private funders that will review research ideas submitted for consideration
    • OnPAR accepts abstracts from CIHR
    • OnPar has now expanded to include pain research projects.

    Founding Partners